期刊文献+

生长激素预处理在卵巢低反应患者体外受精治疗中的应用 被引量:9

Application of growth hormone preconditioning on poor ovarian response patients undergoing in vitro fertilization
下载PDF
导出
摘要 目的 探讨生长激素(GH)预处理对卵巢低反应(POR)患者体外受精(IVF)治疗结局的影响。方法 回顾性分析136例POR患者,其中107例行组间对照,29例行自身对照;分别组间对照比较和自身对照比较促性腺激素(Gn)的使用总量、天数及临床效果。结果 组间对照中预处理组Gn的使用总量和使用天数明显减少,其胚胎数、优质胚胎数、移植率、生化妊娠率、临床妊娠率明显升高,差异均有统计学意义(P<0.05);但其获卵数差异无统计学意义(P>0.05)。自身对照组应用GH预处理后不但Gn的使用时间与总量减少,而且获卵数、胚胎数、优质胚胎数、移植率、生化妊娠数、临床妊娠数均升高,差异有统计学意义(P<0.05)。结论 GH预处理可明显提高POR患者IVF的临床结局,并明显减少Gn的使用总量和天数。 Objective To investigate the effect of growth hormone(GH)preconditioning on the outcome of in vitro fertilization treatment in patients with poor ovarian response(POR).Methods Data of 136 patients with POR,including 107 cases of intergroup control and 29 cases of self-control,were retrospectively analyzed.The total amount and days of Gn administration and its clinical effects were compared between two groups.Results In intergroup control group,the total amount and days of Gn administration were significantly decreased,and the number of embryos,the number of high-quality embryos,transplantation rate,biochemical pregnancy rate and clinical pregnancy rate were significantly increased in patients treated with GH preconditioning,with statistically significant differences(P<0.05);however,there was no significant difference in the number of retrieved oocytes between two groups(P>0.05).In the self-control group,the total amount and days of Gn administration were significantly decreased,and the number of retrieved oocytes,the number of embryos,the number of high-quality embryos,transplantation rate,the number of biochemical pregnancy and clinical pregnancy were significantly increased after treatment with GH preconditioning,with statistically significant differences(P<0.05).Conclusion For POR patients undergoing in vitro fertilization,GH preconditioning may significantly improve the clinical outcome of in vitro fertilization,and reduce the total amount and days of Gn administration.
作者 葛小花 王建业 张雅梦 章志国 郑贤芳 周平 曹云霞 Ge Xiaohua;Wang Jianye;Zhang Yameng(Reproductive Medicine Center,Dept of Obstetrics and Gynecology,The First Affiliated Hospital of Anhui Medical University,Hefei230022;Dept of Obstetrics and Gynecology,Chaohu Affiliated Hospital of Anhui Medical University,Chaohu238000;Anhui Province Key Laboratory of Reproductive Health and Genetics,Anhui Medical University,Hefei230022;Biopreservation and Artificial Organs,Anhui Provincial Engineering Research Center,Hefei230022)
出处 《安徽医科大学学报》 CAS 北大核心 2019年第8期1291-1295,共5页 Acta Universitatis Medicinalis Anhui
基金 国家重点研发计划生殖健康及重大出生缺陷防控研究重点专项项目(项目编号:2017YFC1002000)
关键词 卵巢低反应 生长激素 预处理 治疗结局 poor ovarian response growth hormone preconditioning treatment outcome
  • 相关文献

参考文献2

二级参考文献16

  • 1Kwintkiewicz J, Giudice LC. The interplay of insulin-like growth factors, gonadotropins, and endocrine disruptors in ovar- ian follicular development and function. Semin Reprod Med, 2009,27: 43-51.
  • 2Hull KL, Harvey S. Growth hormone and reproduction: a review of endocrine and autocrine/paracrine interactions.Int J Endo- crinol, 2014, 2014: 234014.
  • 3Fortune JE, Rivera GM, Yang MY. FollicIular development: the role of the follicular microenvironment in selection of the domi- nant follicle. Anim Reprod Sci, 2004, 82:109-126.
  • 4Ferraretti AP, La Marca A, Fauser BC,et al. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod, 2011, 26: 1616-1624.
  • 5Cummins JM, Breen TM, Harrison KL,et al. A formula for scor- ing human embryo growth rates in in vitro fertilization: its value in predicting pregnancy and in comparison with visual estimates of embryo quality. J In Vitro Fert Embryo Transf, 1986, 3:284- 295.
  • 6Rajesh H, Yong YY, Zhu M, et al. Growth hormone deficiency and supplementation at in-vitro fertilisation.Singapore Med J, 2007, 48:514-518.
  • 7Kucuk T, Kozinoglu H, Kaba A. Growth hormone cotreatment within a GnRH agonist long protocol in patients with poor ovar- ian response: a prospective, randomized, clinical trial. J Assist Reprod Genet, 2008, 25:123-127.
  • 8Hughes SM, Huang ZH, Matson PL, et al. Clinical and endocri- nological changes in women following ovulation induction using buserelin acetate/human menopausal gonadotrophin augmented with biosynthetic human growth hormone.Hum Reprod, 1992, 7:770-775.
  • 9Mendoza C, Ruiz-Requena E, Ortega E, et al. Follicular fluid markers of oocyte developmental potential. Hum Reprod, 2002, 17:1017-1022.
  • 10Tesarik J, Hazout A, Mendoza C. Improvement of delivery and live birth rates after ICSI in women aged > 40 years by ovarian co-stimulation with growth hormone. Hum Reprod, 2005, 20: 2536-2541.

共引文献19

同被引文献81

引证文献9

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部